Illumina Inc. ($ILMN) Stock Forecast: Up 5.1% Today

What is Illumina Inc.?

Illumina Inc. (ILMN) is a leading biotechnology company that specializes in genetic sequencing and array-based technologies. The company is known for its innovative products and solutions in the genomics industry.

Why is Illumina Inc. going up?

ILMN stock is up 5.1% on Jan 13, 2025 17:28

• Significant trades in Illumina Inc. (ILMN) by a prominent investment firm could have boosted investor confidence in the stock, leading to a bullish movement.
• Advancements in Illumina's NovaSeq X Series, including software upgrades and new kits, likely generated positive sentiment among investors, contributing to the stock's gains.
• Illumina's strong historical performance, outperforming the market over the past 20 years, may have attracted more investors to the stock, driving up its price further.
• Overall, the combination of positive news catalysts and investor interest in Illumina's innovative genomics technologies likely fueled the bullish movement in ILMN stock today.

ILMN Price Chart

ILMN Technical Analysis

ILMN News

Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics Which Laid Off Over A Quarter Of Its Workforce - ARK Genomic Revolution ETF ( BATS:ARKG ) , Adaptive Biotechnologies ( NASDAQ:ADPT )

Cathie Wood-led Ark Invest made significant trades in five major companies on Friday: Recursion Pharmaceuticals Inc. RXRX, Illumina Inc. ILMN, Intellia Therapeutics Inc. NTLA, Cloudflare Inc. NET, and Adaptive Biotechnologies Corp. ADPT.

https://www.benzinga.com/markets/equities/25/01/42931987/cathie-woods-ark-invest-loads-up-on-intellia-therapeutics-which-laid-off-over-a-quarter-of-its-w

ILMN Stock Set to Gain From Latest Updates to the NovaSeq X Series

Illumina advances NovaSeq X Series with a software upgrade and the new 25B 100-cycle and 200-cycle kits.

https://www.zacks.com/stock/news/2393436/ilmn-stock-set-to-gain-from-latest-updates-to-the-novaseq-x-series

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today - Illumina ( NASDAQ:ILMN )

Illumina ILMN has outperformed the market over the past 20 years by 10.57% on an annualized basis producing an average annual return of 18.97%. Currently, Illumina has a market capitalization of $22.18 billion.

https://www.benzinga.com/insights/news/25/01/42854471/100-invested-in-this-stock-20-years-ago-would-be-worth-this-much-today

Trending Today

Solana ($SOL) Crypto Forecast: Up 5.2% Today

Render ($RENDER) Crypto Forecast: Up 5.2% Today

Litecoin ($LTC) Crypto Forecast: Up 6.5% Today

Polkadot ($DOT) Crypto Forecast: Up 6.0% Today

Novo Nordisk A/S ($NVO) Stock Forecast: Down 5.0% Today

XRP ($XRP) Crypto Forecast: Up 5.3% Today

Ethereum ($ETH) Crypto Forecast: Up 5.1% Today

dogwifhat ($WIF) Crypto Forecast: Up 5.3% Today

Sonic (prev. FTM) ($S) Crypto Forecast: Up 7.1% Today

Fetch.ai ($FET) Crypto Forecast: Up 5.7% Today

Illumina Inc. Price History

13.08.2024 - ILMN Stock was up 6.1%

• Illumina (ILMN) exhibited a notable bullish trend today, likely influenced by:
• Recognition of the stock's impressive long-term performance, drawing in investors seeking stable returns.
• Mention of a recent earnings surge, potentially boosting confidence in the company's growth outlook and attracting more buyers.
• Positive market sentiment towards Illumina's innovative technologies and the promising opportunities within the biotech industry.

02.09.2024 - ILMN Stock was up 5.8%

• Illumina's significant surge in the market today can be linked to its remarkable long-term performance, averaging a 20.33% annual return over the last two decades.
• Investor confidence in Illumina's future within the biotechnology industry may be fueling the increased demand for its stock.
• The company's market capitalization of $20.38 billion highlights investors' trust in its innovative technologies and potential for further expansion.
• Taken together, Illumina's consistent market outperformance and ongoing advancements in genetic sequencing likely played a role in today's positive market movement.

13.00.2025 - ILMN Stock was up 5.1%

• Significant trades in Illumina Inc. (ILMN) by a prominent investment firm could have boosted investor confidence in the stock, leading to a bullish movement.
• Advancements in Illumina's NovaSeq X Series, including software upgrades and new kits, likely generated positive sentiment among investors, contributing to the stock's gains.
• Illumina's strong historical performance, outperforming the market over the past 20 years, may have attracted more investors to the stock, driving up its price further.
• Overall, the combination of positive news catalysts and investor interest in Illumina's innovative genomics technologies likely fueled the bullish movement in ILMN stock today.

22.10.2024 - ILMN Stock was up 5.2%

• Today, Illumina's stock saw an upturn following the announcement of the expansion of its TruSight Oncology portfolio with the release of the TSO 500 v2 assay.
• The market responded favorably to this news, anticipating that the new assay will improve comprehensive genomic profiling (CGP) of tumors, demonstrating Illumina's dedication to advancing cancer research and treatment.
• Investors perceive this expansion as a strategic decision that may drive future revenue growth for Illumina, fostering increased confidence and stock purchases.

04.10.2024 - ILMN Stock was up 3.0%

• Illumina (ILMN) experienced a bullish movement today, likely driven by positive analyst projections for key metrics in its Q3 earnings.
• The long-term outperformance of Illumina in the market, with an impressive average annual return of 21.08% over the past 20 years, has also contributed to investor confidence and interest in the stock.
• The anticipation of strong performance in the quarter ended September 2024, as indicated by analyst forecasts, has further fueled bullish sentiment among investors.
• Overall, Illumina's consistent growth, market leadership in genomics, and positive earnings outlook have propelled the stock to a strong bullish movement today.

09.11.2024 - ILMN Stock was up 4.5%

• The strong bullish movement in ILMN today could be attributed to positive market sentiment and potential investor optimism.
• A 9.3% decline since the last earnings report may have sparked interest among investors looking for a potential rebound opportunity.
• Investors might be speculating on positive future earnings estimates or expecting new developments in Illumina's technology and product offerings.
• Overall, the bullish movement in ILMN today could be a result of renewed confidence in the company's growth prospects and potential for a rebound from previous setbacks.

18.11.2024 - ILMN Stock was down 5.2%

• Removal from the Nasdaq-100 Index created a bearish sentiment, indicating a loss of exposure and institutional interest.
• Lackluster performance in comparison to iShares Core S&P Mid-Cap ETF (IJH) potentially raised investor unease and led to selling.
• Being taken out of the index may have caused index-based funds and institutional investors to adjust their holdings, resulting in higher sell-offs and pushing the stock price down.

07.07.2024 - ILMN Stock was up 5.4%

• Better-than-expected second-quarter sales results were reported by Illumina, leading to an increase in analyst forecasts and a bullish movement in the stock.
• Citigroup raised Illumina's stock target and maintained a positive rating due to strong margins, further boosting investor confidence.
• Despite a revenue decline amid market challenges, Illumina managed to improve its margins, which was well-received by investors and contributed to the bullish movement in the stock.
• The positive earnings report and analyst upgrades likely fueled investor optimism and drove the stock higher throughout the trading day.

13.07.2024 - ILMN Stock was down 5.2%

• Illumina reported surpassing Q2 earnings expectations, although it adjusted its 2024 sales forecast downwards, reflecting difficulties within the global macroeconomic landscape.
• Anticipating a decrease in yearly sales within its primary segment due to constraints in biotech funding, Illumina's future outlook is affected.
• Despite the negative stock movement, analysts have raised their price target for Illumina, showcasing faith in the company's potential longevity.
• The downward movement in Illumina's stock is possibly linked to a blend of factors including the mixed earnings report, revised sales forecast, and uncertainties surrounding future demand in the gene sequencing industry amidst biotech funding challenges.

08.07.2024 - ILMN Stock was up 5.6%

• Illumina's shares surged as analysts increased their price targets post strong Q2 results, indicating confidence in the company's performance and growth potential.
• The decision to raise Illumina's stock target, coupled with a maintained strong rating from Citi, underscores a positive view on the company's profitability and margins.
• Despite a revenue dip due to market challenges, Illumina enhanced its margins, demonstrating resilience and effective cost management.
• The upward trend in Illumina's stock value can be attributed to improved financial performance, optimistic analyst predictions, and overall market positivity propelling the stock upwards.

14.07.2024 - ILMN Stock was up 5.6%

• Illumina, Inc. received a reaffirmation of a "Buy" rating, with new product launches boosting the growth outlook, which likely contributed to the bullish movement.
• Despite beating Q2 earnings expectations, Illumina lowered its 2024 sales view, indicating potential concerns about future performance.
• Activist pressure could be driving some market excitement and speculation around potential strategic changes within the company.
• The overall positive sentiment around gene editing stocks and the potential for transformative medicine may have also positively influenced Illumina's stock performance today.

15.07.2024 - ILMN Stock was up 5.1%

• Illumina's solid performance over the past 20 years, with an annualized return of 21.21%, likely contributed to the bullish movement today.
• The reaffirmation of a "Buy" rating by a prominent analyst, citing new product launches boosting growth outlook, could have instilled confidence in investors and further fueled the positive momentum.
• Despite surpassing Q2 earnings expectations, the update on lowering 2024 sales view might have initially caused some concerns but was overshadowed by the overall positive sentiment towards the company.
• The activist pressure from Icahn Enterprises may have initially raised some uncertainties, but the market seemed to focus more on the company's long-term growth potential and resilience.